{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:48:16Z","timestamp":1792813696667,"version":"4.5.0"},"reference-count":249,"publisher":"IOP Publishing","issue":"2","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"National Institute of Health","award":["K08EY036955-01"],"award-info":[{"award-number":["K08EY036955-01"]}]},{"name":"Robert Machemer Foundation"},{"DOI":"10.13039\/100010310","name":"E. Matilda Ziegler Foundation for the Blind","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010310","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007817","name":"Alcon Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007817","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"crossref","award":["M2025004N"],"award-info":[{"award-number":["M2025004N"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Biofabrication"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite the rapid pace of biomedical engineering research, translating developed products into clinical practice remains challenging due to regulations, manufacturing, and long-term\n                    <jats:italic>in vivo<\/jats:italic>\n                    safety. The eye offers advantageous features to lower translational hurdles, making it an ideal clinical target and an approachable testbed for biofabricated implants. However, eyes also have anatomical and physiological barriers that hinder conventional ophthalmic delivery routes, leading to poor drug bioavailability. Advances in biofabrication and biomaterials used in ophthalmic therapeutic implants have the potential to address the current challenges. This review will explore biomaterials, biofabrication methods, and possible ocular implantation sites from the perspective of developing effective therapeutic implants. It also examines clinically available products and current clinical trials, along with recent advancements and next-generation technologies in ophthalmic therapeutic delivery implants. This review aims to provide insights that facilitate the translation of emerging ocular therapeutics into clinically available treatments.\n                  <\/jats:p>","DOI":"10.1088\/1758-5090\/ae49fe","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:56:40Z","timestamp":1771973800000},"page":"022004","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Implantable ocular therapeutic systems: an insight into their clinical potential in the long-term treatment of ocular diseases"],"prefix":"10.1088","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6918-6564","authenticated-orcid":true,"given":"Hyeonji","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nae-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Abdollahramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8981-3153","authenticated-orcid":true,"given":"Gia-Han","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-5297","authenticated-orcid":true,"given":"Daanyal","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3188-8187","authenticated-orcid":true,"given":"Olivia","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-1741","authenticated-orcid":false,"given":"Vinit B","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Myung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"DeBoer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"bfae49febib1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ccd.26217","type":"journal-article","article-title":"Clinical outcomes in real\u2010world patients with bifurcation lesions receiving Xience V everolimus\u2010eluting stents: four\u2010year results from the Xience V USA study","volume":"88","author":"Hermiller","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"bfae49febib2","doi-asserted-by":"publisher","first-page":"152S","DOI":"10.1097\/01.prs.0000222534.79915.d3","type":"journal-article","article-title":"The efficacy of Apligraf in the treatment of diabetic foot ulcers","volume":"117","author":"Dinh","year":"2006","journal-title":"Plast. Reconstructive Surg."},{"key":"bfae49febib3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s44222-024-00269-z","type":"journal-article","article-title":"Clinical translation of personalized bioengineered implant scaffolds","volume":"3","author":"Xu","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"bfae49febib4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2019.05.034","type":"journal-article","article-title":"Hydrogel-based ocular drug delivery systems: emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations","volume":"306","author":"Cooper","year":"2019","journal-title":"J. Control. Release"},{"key":"bfae49febib5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0192623320978396","type":"journal-article","article-title":"Immunology and pathology in ocular drug development","volume":"49","author":"Ramos","year":"2021","journal-title":"Toxicol. Pathol."},{"key":"bfae49febib6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","type":"journal-article","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"bfae49febib7","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41433-020-0809-0","type":"journal-article","article-title":"Advances in ocular drug delivery systems","volume":"34","author":"Kang-Mieler","year":"2020","journal-title":"Eye"},{"key":"bfae49febib8","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s10792-023-02637-x","type":"journal-article","article-title":"Implantable sustained-release drug deliver systems: a revolution for ocular therapeutics","volume":"43","author":"Cong","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"bfae49febib9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","type":"journal-article","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog. Retinal Eye Res."},{"key":"bfae49febib10","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207603","type":"journal-article","article-title":"Biopolymeric coatings for local release of therapeutics from biomedical implants","volume":"10","author":"Talebian","year":"2023","journal-title":"Adv. Sci."},{"key":"bfae49febib11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/gels9120933","type":"journal-article","article-title":"Sustained release of voriconazole using 3D-crosslinked hydrogel rings and rods for use in corneal drug delivery","volume":"9","author":"Rakhmetova","year":"2023","journal-title":"Gels"},{"key":"bfae49febib12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124699","type":"journal-article","article-title":"Macrolide-loaded nanofibrous inserts with polycaprolactone and cellulose acetate base for sustained ocular delivery: pharmacokinetic study in Rabbit\u2019s eye","volume":"665","author":"Taghe","year":"2024","journal-title":"Int. J. Pharm."},{"key":"bfae49febib13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1515\/epoly.2009.9.1.1466","type":"journal-article","article-title":"Materials for intraocular lenses (IOLs): review of developments to achieve biocompatibility","volume":"9","author":"Tripti","year":"2009","journal-title":"e-Polymers"},{"key":"bfae49febib14","doi-asserted-by":"publisher","first-page":"52959","DOI":"10.1039\/C4RA08060B","type":"journal-article","article-title":"Synthesis of MA POSS\u2013PMMA as an intraocular lens material with high light transmittance and good cytocompatibility","volume":"4","author":"Wang","year":"2014","journal-title":"RSC Adv."},{"key":"bfae49febib15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.787644","type":"journal-article","article-title":"Considerations for polymers used in ocular drug delivery","volume":"8","author":"Allyn","year":"2022","journal-title":"Front. Med."},{"key":"bfae49febib16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1021\/acs.biomac.0c01525","type":"journal-article","article-title":"Polymeric materials for eye surface and intraocular applications","volume":"22","author":"Karayilan","year":"2021","journal-title":"Biomacromolecules"},{"key":"bfae49febib17","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.addr.2005.09.005","type":"journal-article","article-title":"Intraocular sustained drug delivery using implantable polymeric devices","volume":"57","author":"Yasukawa","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"bfae49febib18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1517\/17425247.3.2.261","type":"journal-article","article-title":"Drug delivery from ocular implants","volume":"3","author":"Yasukawa","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"bfae49febib19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/jab.770040209","type":"journal-article","article-title":"A comparison of a new polypropylene suture with Prolene","volume":"4","author":"Chu","year":"1993","journal-title":"J. Appl. Biomater."},{"key":"bfae49febib20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/mabi.201000298","type":"journal-article","article-title":"Development of a new polypropylene\u2010based suture: plasma grafting, surface treatment, characterization, and biocompatibility studies","volume":"11","author":"Saxena","year":"2011","journal-title":"Macromol. Biosci."},{"key":"bfae49febib21","doi-asserted-by":"publisher","DOI":"10.1002\/app.50969","type":"journal-article","article-title":"Silicone\u2010based biomaterials for biomedical applications: antimicrobial strategies and 3D printing technologies","volume":"138","author":"Zare","year":"2021","journal-title":"J. Appl. Polym. Sci."},{"key":"bfae49febib22","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.3390\/ma17143454","type":"journal-article","article-title":"Application of silicone in ophthalmology: a review","volume":"17","author":"Mladenovic","year":"2024","journal-title":"Materials"},{"key":"bfae49febib23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0142-9612(00)00237-4","type":"journal-article","article-title":"Ocular biomaterials and implants","volume":"22","author":"Lloyd","year":"2001","journal-title":"Biomaterials"},{"key":"bfae49febib24","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1039\/D4SM00016A","type":"journal-article","article-title":"Ultrasoft silicone gels with tunable refractive index for traction force microscopy","volume":"20","author":"Terdik","year":"2024","journal-title":"Soft Matter"},{"key":"bfae49febib25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4236\/ojopm.2013.34018","type":"journal-article","article-title":"Significant improvement of mechanical properties for polyvinyl alcohol film prepared from freeze\/thaw cycled gel","volume":"3","author":"Fukumori","year":"2013","journal-title":"Open J. Org. Polym. Mater."},{"key":"bfae49febib26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jiec.2020.06.017","type":"journal-article","article-title":"A comprehensive review on polymeric hydrogel and its composite: matrices of choice for bone and cartilage tissue engineering","volume":"89","author":"Tran","year":"2020","journal-title":"J. Ind. Eng. Chem."},{"key":"bfae49febib27","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.3390\/polym15183782","type":"journal-article","article-title":"Enhanced mechanical properties of PVA hydrogel by low-temperature segment self-assembly vs. freeze\u2013thaw cycles","volume":"15","author":"Wu","year":"2023","journal-title":"Polymers"},{"key":"bfae49febib28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/pharmaceutics13050701","type":"journal-article","article-title":"Polymeric implants for the treatment of intraocular eye diseases: trends in biodegradable and non-biodegradable materials","volume":"13","author":"Garc\u00eda-Estrada","year":"2021","journal-title":"Pharmaceutics"},{"key":"bfae49febib29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.biotechadv.2018.11.008","type":"journal-article","article-title":"Biomaterials of PVA and PVP in medical and pharmaceutical applications: perspectives and challenges","volume":"37","author":"Teodorescu","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"bfae49febib30","first-page":"279","type":"book","article-title":"Application of hydrogel template strategy in ocular drug delivery","author":"Shin","year":"2017"},{"key":"bfae49febib31","article-title":"Poly (2-hydroxyethyl methacrylate) hydrogels for contact lens applications\u2013a review","author":"Saptaji","year":"2021","type":"other"},{"key":"bfae49febib32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3109\/02713683.2014.978476","type":"journal-article","article-title":"New hydrophobic IOL materials and understanding the science of glistenings","volume":"40","author":"Tetz","year":"2015","journal-title":"Curr. Eye Res."},{"key":"bfae49febib33","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.3390\/ijms22126376","type":"journal-article","article-title":"pHEMA: an overview for biomedical applications","volume":"22","author":"Zare","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"bfae49febib34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4103\/2278-344X.107844","type":"journal-article","article-title":"pHEMA hydrogels: devices for ocular drug delivery","volume":"1","author":"Tomar","year":"2012","journal-title":"Int. J. Health Allied Sci."},{"key":"bfae49febib35","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.3390\/ijms15033640","type":"journal-article","article-title":"An overview of poly (lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering","volume":"15","author":"Gentile","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"bfae49febib36","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s11095-010-0232-5","type":"journal-article","article-title":"PLGA erosion: solubility-or diffusion-controlled?","volume":"27","author":"K\u00f6rber","year":"2010","journal-title":"Pharm. Res."},{"key":"bfae49febib37","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.drudis.2019.05.031","type":"journal-article","article-title":"Recent advances in intraocular sustained-release drug delivery devices","volume":"24","author":"Cao","year":"2019","journal-title":"Drug Discovery Today"},{"key":"bfae49febib38","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/OPTH.S13775","type":"journal-article","article-title":"Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex\u00ae) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion","volume":"5","author":"Chan","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"bfae49febib39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/tvst.8.1.12","type":"journal-article","article-title":"Characterization of biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of ranibizumab","volume":"8","author":"Liu","year":"2019","journal-title":"Trans. Vis. Sci. Technol."},{"key":"bfae49febib40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/02713683.2018.1533983","type":"journal-article","article-title":"Biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of bioactive aflibercept in vitro","volume":"44","author":"Liu","year":"2019","journal-title":"Curr. Eye Res."},{"key":"bfae49febib41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jconrel.2013.01.007","type":"journal-article","article-title":"Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation","volume":"167","author":"Chennamaneni","year":"2013","journal-title":"J. Control. Release"},{"key":"bfae49febib42","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s11095-014-1410-7","type":"journal-article","article-title":"Pharmacokinetics and efficacy of bioerodible dexamethasone implant in concanavalin A-induced uveitic cataract rabbit model","volume":"31","author":"Chennamaneni","year":"2014","journal-title":"Pharm. Res."},{"key":"bfae49febib43","article-title":"NDA 211911 Durysta (bimatoprost implant) for intracameral administration","author":"Nevitt","type":"web-resource"},{"key":"bfae49febib44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103676","type":"journal-article","article-title":"Ocular application of electrospun materials for drug delivery and cellular therapies","volume":"28","author":"Mishra","year":"2023","journal-title":"Drug Discovery Today"},{"key":"bfae49febib45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.addr.2016.06.012","type":"journal-article","article-title":"Physical and mechanical properties of PLA, and their functions in widespread applications\u2014a comprehensive review","volume":"107","author":"Farah","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"bfae49febib46","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/126463","type":"journal-article","article-title":"Intravitreal devices for the treatment of vitreous inflammation","volume":"2012","author":"Christoforidis","year":"2012","journal-title":"Mediators Inflamm."},{"key":"bfae49febib47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cej.2018.01.010","type":"journal-article","article-title":"Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems","volume":"340","author":"Da Silva","year":"2018","journal-title":"Chem. Eng. J."},{"key":"bfae49febib48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/polym16060817","type":"journal-article","article-title":"The potential for foreign body reaction of implanted poly-l-lactic acid: a systematic review","volume":"16","author":"Nonhoff","year":"2024","journal-title":"Polymers"},{"key":"bfae49febib49","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","type":"journal-article","article-title":"Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2)","volume":"81","author":"Bacharach","year":"2021","journal-title":"Drugs"},{"key":"bfae49febib50","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/sj.eye.6700559","type":"journal-article","article-title":"Biology of the corneal endothelium in health and disease","volume":"17","author":"Bourne","year":"2003","journal-title":"Eye"},{"key":"bfae49febib51","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.actbio.2010.02.002","type":"journal-article","article-title":"Mechanical and microstructural properties of polycaprolactone scaffolds with 1-D, 2-D, and 3-D orthogonally oriented porous architectures produced by selective laser sintering","volume":"6","author":"Eshraghi","year":"2010","journal-title":"Acta Biomater."},{"key":"bfae49febib52","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1039\/b820162p","type":"journal-article","article-title":"Synthesis of polycaprolactone: a review","volume":"38","author":"Labet","year":"2009","journal-title":"Chem. Soc. Rev."},{"key":"bfae49febib53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/pharmaceutics15010243","type":"journal-article","article-title":"Fabrication and characterisation of 3D-printed triamcinolone acetonide-loaded polycaprolactone-based ocular implants","volume":"15","author":"Annuryanti","year":"2023","journal-title":"Pharmaceutics"},{"key":"bfae49febib54","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtcomm.2021.102402","type":"journal-article","article-title":"Use of polycaprolactone in corneal tissue engineering: a review","volume":"27","author":"Salehi","year":"2021","journal-title":"Mater. Today Commun."},{"key":"bfae49febib55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022507","type":"journal-article","article-title":"Biocompatibility and biodegradation studies of subconjunctival implants in rabbit eyes","volume":"6","author":"Peng","year":"2011","journal-title":"PLoS One"},{"key":"bfae49febib56","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1167\/iovs.08-2969","type":"journal-article","article-title":"Poly-\u03f5-caprolactone intravitreous devices: an in vivo study","volume":"50","author":"Silva-Cunha","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib57","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201703606","type":"journal-article","article-title":"Microfabricated drug delivery devices: design, fabrication, and applications","volume":"27","author":"Zhang","year":"2017","journal-title":"Adv. Funct. Mater."},{"key":"bfae49febib58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s11095-006-9906-4","type":"journal-article","article-title":"Application of micro-and nano-electromechanical devices to drug delivery","volume":"23","author":"Staples","year":"2006","journal-title":"Pharm. Res."},{"key":"bfae49febib59","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.addr.2012.02.005","type":"journal-article","article-title":"Reservoir-based drug delivery systems utilizing microtechnology","volume":"64","author":"Stevenson","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"bfae49febib60","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1021\/acs.biomac.8b00218","type":"journal-article","article-title":"Translatable high drug loading drug delivery systems based on biocompatible polymer nanocarriers","volume":"19","author":"Chen","year":"2018","journal-title":"Biomacromolecules"},{"key":"bfae49febib61","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/adb555","type":"journal-article","article-title":"Thiolated gellan gum\/polyethylene glycol diacrylate hydrogels containing timolol maleate-loaded chitosan nanoparticles for ophthalmic delivery","volume":"20","author":"Shajari","year":"2025","journal-title":"Biomed. Mater."},{"key":"bfae49febib62","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202100214","type":"journal-article","article-title":"Extending drug release from implants via transcutaneous refilling with solid therapeutics","volume":"5","author":"Di Trani","year":"2022","journal-title":"Adv. Ther."},{"key":"bfae49febib63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jconrel.2016.02.012","type":"journal-article","article-title":"In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery","volume":"226","author":"Maulvi","year":"2016","journal-title":"J. Control. Release"},{"key":"bfae49febib64","doi-asserted-by":"publisher","first-page":"33474","DOI":"10.1021\/acsami.5c03985","type":"journal-article","article-title":"Refillable intraocular drug-eluting implant","volume":"17","author":"Kim","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"bfae49febib65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101464","type":"journal-article","article-title":"Optimization of dip-coating methods for the fabrication of coated microneedles for drug delivery","volume":"55","author":"Liang","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"bfae49febib66","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/02713683.2024.2344164","type":"journal-article","article-title":"Stereolithographic rapid prototyping of clear, foldable, non-refractive intraocular lens designs: a proof-of-concept study","volume":"49","author":"Hidalgo-Alvarez","year":"2024","journal-title":"Curr. Eye Res."},{"key":"bfae49febib67","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41378-021-00284-9","type":"journal-article","article-title":"Optimization of the fused deposition modeling-based fabrication process for polylactic acid microneedles","volume":"7","author":"Wu","year":"2021","journal-title":"Microsyst. Nanoeng."},{"key":"bfae49febib68","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3390\/pharmaceutics13091421","type":"journal-article","article-title":"3D printed punctal plugs for controlled ocular drug delivery","volume":"13","author":"Xu","year":"2021","journal-title":"Pharmaceutics"},{"key":"bfae49febib69","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.addr.2003.08.012","type":"journal-article","article-title":"Integrated microsystems for controlled drug delivery","volume":"56","author":"Razzacki","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"bfae49febib70","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/pharmaceutics15041062","type":"journal-article","article-title":"Nanofibers in ocular drug targeting and tissue engineering: their importance, advantages, advances, and future perspectives","volume":"15","author":"Uzel","year":"2023","journal-title":"Pharmaceutics"},{"key":"bfae49febib71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2023.100847","type":"journal-article","article-title":"Contact lens as an emerging platform for ophthalmic drug delivery: a systematic review","volume":"18","author":"Yang","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"bfae49febib72","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijpharm.2017.03.082","type":"journal-article","article-title":"Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions","volume":"525","author":"Garcia-Millan","year":"2017","journal-title":"Int. J. Pharm."},{"key":"bfae49febib73","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijpharm.2013.11.058","type":"journal-article","article-title":"Microparticles produced by the hydrogel template method for sustained drug delivery","volume":"461","author":"Lu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"bfae49febib74","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1109\/TBME.2015.2484379","type":"journal-article","article-title":"Biomimetic accommodating intraocular lens using a valved deformable liquid balloon","volume":"63","author":"DeBoer","year":"2015","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"bfae49febib75","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1038\/s41467-018-06981-w","type":"journal-article","article-title":"Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery","volume":"9","author":"Than","year":"2018","journal-title":"Nat. Commun."},{"key":"bfae49febib76","first-page":"6202","type":"journal-article","article-title":"Evaluation of refillable drug-eluting intraocular implant","volume":"66","author":"Kim","year":"2025","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/automation6040075","type":"journal-article","article-title":"Design and validation of a low-cost automated dip-coater system for laboratory applications","volume":"6","author":"Guzm\u00e1n-Valdivia","year":"2025","journal-title":"Automation"},{"key":"bfae49febib78","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3390\/nano15151187","type":"journal-article","article-title":"Coating metal\u2013organic frameworks (MOFs) and associated composites on electrodes, thin film polymeric materials, and glass surfaces","volume":"15","author":"Hasan","year":"2025","journal-title":"Nanomaterials"},{"key":"bfae49febib79","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/md21030147","type":"journal-article","article-title":"Chitosan-based biomaterials: insights into chemistry, properties, devices, and their biomedical applications","volume":"21","author":"Petroni","year":"2023","journal-title":"Mar. Drugs"},{"key":"bfae49febib80","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1039\/c3ra46881j","type":"journal-article","article-title":"Enhancement and wettability of self-assembled GO sheets as interfacial layers of CF\/PI composites","volume":"4","author":"Niu","year":"2014","journal-title":"RSC Adv."},{"key":"bfae49febib81","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1021\/acsapm.4c04077","type":"journal-article","article-title":"Dip-coating fabrication of all-polymer multilayer photonic crystals through 3D printer conversion","volume":"7","author":"Martusciello","year":"2025","journal-title":"ACS Appl. Polym. Mater."},{"key":"bfae49febib82","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s10971-016-4197-7","type":"journal-article","article-title":"Dip-coating for fibrous materials: mechanism, methods and applications","volume":"81","author":"Tang","year":"2017","journal-title":"J. Sol-Gel Sci. Technol."},{"key":"bfae49febib83","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/38699","type":"journal-article","article-title":"Continuous formation of supported cubic and hexagonal mesoporous films by sol\u2013gel dip-coating","volume":"389","author":"Lu","year":"1997","journal-title":"Nature"},{"key":"bfae49febib84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jpowsour.2012.09.103","type":"journal-article","article-title":"Dip\u2013spin coating of reticulated vitreous carbon with composite materials to act as an electrode for 3D microstructured lithium ion batteries","volume":"224","author":"Roberts","year":"2013","journal-title":"J. Power Sources"},{"key":"bfae49febib85","first-page":"1461","type":"conference-proceedings","article-title":"A parylene bellows electrochemical actuator for intraocular drug delivery","author":"Li","year":"2009"},{"key":"bfae49febib86","first-page":"1","type":"conference-proceedings","article-title":"Controlled delivery of antiangiogenic drug to human eye tissue using a MEMS device","author":"Pirmoradi","year":"2013"},{"key":"bfae49febib87","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1038\/s41467-022-32859-z","type":"journal-article","article-title":"Self-shrinking soft demoulding for complex high-aspect-ratio microchannels","volume":"13","author":"Fan","year":"2022","journal-title":"Nat. Commun."},{"key":"bfae49febib88","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/mi17010074","type":"journal-article","article-title":"A novel technique for quality control of microinjection molding","volume":"17","author":"Daoud","year":"2026","journal-title":"Micromachines"},{"key":"bfae49febib89","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/mi12030319","type":"journal-article","article-title":"Fabrication methods for microfluidic devices: an overview","volume":"12","author":"Scott","year":"2021","journal-title":"Micromachines"},{"key":"bfae49febib90","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1021\/acs.molpharmaceut.5c00808","type":"journal-article","article-title":"Infill-modulated, bioerodible, and biocompatible ocular inserts for tunable acyclovir release via direct powder extrusion 3D printing","volume":"22","author":"Das","year":"2025","journal-title":"Mol. Pharm."},{"key":"bfae49febib91","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.survophthal.2022.01.004","type":"journal-article","article-title":"Applications of three-dimensional printing in ophthalmology","volume":"67","author":"Tsui","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"bfae49febib92","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/jpp\/rgab173","type":"journal-article","article-title":"Development of 3D printed drug-eluting contact lenses","volume":"74","author":"Mohamdeen","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"key":"bfae49febib93","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1248\/bpb.b23-00443","type":"journal-article","article-title":"Fabrication of 3D-printed contact lens composed of polyethylene glycol diacrylate for controlled release of Azithromycin","volume":"46","author":"Goto","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"bfae49febib94","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1007\/s43441-025-00812-z","type":"journal-article","article-title":"The challenges in the regulatory approval of additive-manufactured medical devices: a quantitative survey","volume":"59","author":"Connole","year":"2025","journal-title":"Ther. Innov. Regulatory Sci."},{"key":"bfae49febib95","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/pharmaceutics17020219","type":"journal-article","article-title":"3D-printed contact lenses to release polyvinyl alcohol as a therapeutic agent for the treatment of dry eyes","volume":"17","author":"Garg","year":"2025","journal-title":"Pharmaceutics"},{"key":"bfae49febib96","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3390\/pharmaceutics14112411","type":"journal-article","article-title":"Fused deposition modeling (FDM) 3D printing of the thermo-sensitive peptidomimetic drug enalapril maleate","volume":"14","author":"Hoffmann","year":"2022","journal-title":"Pharmaceutics"},{"key":"bfae49febib97","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/bioengineering12090924","type":"journal-article","article-title":"Impact of disinfection and sterilization on 3D-printing resin performance for surgical guides in cardiac ablation surgery","volume":"12","author":"Kronenberger","year":"2025","journal-title":"Bioengineering"},{"key":"bfae49febib98","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10544-009-9313-9","type":"journal-article","article-title":"A passive MEMS drug delivery pump for treatment of ocular diseases","volume":"11","author":"Lo","year":"2009","journal-title":"Biomed. Microdevices"},{"key":"bfae49febib99","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/pharmaceutics17050599","type":"journal-article","article-title":"Ocular drug delivery: emerging approaches and advances","volume":"17","author":"Gade","year":"2025","journal-title":"Pharmaceutics"},{"key":"bfae49febib100","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1039\/D5LC00499C","type":"journal-article","article-title":"Microfluidic technologies for wearable and implantable biomedical devices","volume":"25","author":"Wang","year":"2025","journal-title":"Lab Chip"},{"key":"bfae49febib101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.213124","type":"journal-article","article-title":"Recent advancements in polymeric nanofibers for ophthalmic drug delivery and ophthalmic tissue engineering","volume":"141","author":"Sakpal","year":"2022","journal-title":"Biomater. Adv."},{"key":"bfae49febib102","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/pharmaceutics13101637","type":"journal-article","article-title":"A systematic review of drug-loaded electrospun nanofiber-based ophthalmic inserts","volume":"13","author":"Omer","year":"2021","journal-title":"Pharmaceutics"},{"key":"bfae49febib103","article-title":"Development of a biodegradable polymer-based implant to release dual drugs for post-operative management of cataract surgery","author":"Guru","year":"2024","type":"other"},{"key":"bfae49febib104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12348-025-00494-6","type":"journal-article","article-title":"Subconjunctival dexamethasone implant (Ozurdex\u00ae) in the management of refractory non-infectious anterior scleritis","volume":"15","author":"Ganbold","year":"2025","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"bfae49febib105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125507","type":"journal-article","article-title":"Acetazolamide-loaded intravitreal implants for the treatment of glaucoma: formulation, physicochemical characterization and assessment of in vitro and in vivo safety","volume":"674","author":"da Silva","year":"2025","journal-title":"Int. J. Pharm."},{"key":"bfae49febib106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113659","type":"journal-article","article-title":"Delivery of a novel neuroprotective compound to the retina in rat and rabbit animal models","volume":"382","author":"Garrett","year":"2025","journal-title":"J. Control. Release"},{"key":"bfae49febib107","article-title":"Emerging technologies for ocular drug delivery","author":"Vora","year":"2025","type":"other"},{"key":"bfae49febib108","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","type":"journal-article","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"bfae49febib109","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","type":"journal-article","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discovery Today"},{"key":"bfae49febib110","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","type":"journal-article","article-title":"Drug delivery systems for vitreoretinal diseases","volume":"23","author":"Yasukawa","year":"2004","journal-title":"Prog. Retinal Eye Res."},{"key":"bfae49febib111","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","type":"journal-article","article-title":"Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"bfae49febib112","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","type":"journal-article","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"bfae49febib113","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","type":"journal-article","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharm."},{"key":"bfae49febib114","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/bjo.2009.174912","type":"journal-article","article-title":"Gene therapy for ocular diseases","volume":"95","author":"Liu","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"bfae49febib115","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1021\/js9802594","type":"journal-article","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"bfae49febib116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097555","type":"journal-article","article-title":"Evaluation of a prednisolone acetate-loaded subconjunctival implant for the treatment of recurrent uveitis in a rabbit model","volume":"9","author":"Ang","year":"2014","journal-title":"PLoS One"},{"key":"bfae49febib117","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1208\/s12249-025-03142-3","type":"journal-article","article-title":"Injectable PLGA-based in situ forming subconjunctival implant for sustained ocular delivery of ketotifen fumarate: formulation, drug release, and biocompatibility studies","volume":"26","author":"Mita","year":"2025","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"bfae49febib118","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","type":"journal-article","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"bfae49febib119","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000108117","type":"journal-article","article-title":"Transport barriers in transscleral drug delivery for retinal diseases","volume":"39","author":"Kim","year":"2007","journal-title":"Ophthalmic Res."},{"key":"bfae49febib120","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17425247.2023.2219053","type":"journal-article","article-title":"Sustained release ocular drug delivery systems for glaucoma therapy","volume":"20","author":"Al-Qaysi","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"bfae49febib121","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/17425247.1.1.99","type":"journal-article","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin. Drug Deliv."},{"key":"bfae49febib122","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.addr.2006.07.025","type":"journal-article","article-title":"Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling","volume":"58","author":"Ranta","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"bfae49febib123","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","type":"journal-article","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"key":"bfae49febib124","first-page":"137","type":"book","article-title":"Nanotechnology for ocular drug delivery","author":"Agarwal","year":"2018"},{"key":"bfae49febib125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoint.2025.100168","type":"journal-article","article-title":"Effectiveness of intracameral antibiotics in reducing postoperative endophthalmitis risk after cataract surgery: a meta-analysis","volume":"2","author":"Serhan","year":"2025","journal-title":"AJO Int."},{"key":"bfae49febib126","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2147\/OPTH.S165722","type":"journal-article","article-title":"Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy","volume":"12","author":"Shah","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"bfae49febib127","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/jop.2022.0144","type":"journal-article","article-title":"Intracameral drug delivery: a review of agents, indications, and outcomes","volume":"39","author":"Gautam","year":"2023","journal-title":"J. Ocular Pharmacol. Ther."},{"key":"bfae49febib128","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40123-020-00285-3","type":"journal-article","article-title":"Distribution of 14C-latanoprost following a single intracameral administration versus repeated topical administration","volume":"9","author":"Shen","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"bfae49febib129","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/DDDT.S506520","type":"journal-article","article-title":"Bimatoprost intracameral implant (Durysta\u00ae): a new era in glaucoma management through sustained-release innovation","volume":"19","author":"Vagiakis","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"bfae49febib130","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/OPTH.S498431","type":"journal-article","article-title":"Travoprost intracameral implant in eyes with glaucoma or ocular hypertension: early short-term real-world outcomes","volume":"19","author":"Teymoorian","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"bfae49febib131","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","type":"journal-article","article-title":"Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1)","volume":"127","author":"Medeiros","year":"2020","journal-title":"Ophthalmology"},{"key":"bfae49febib132","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/jop.2022.0137","type":"journal-article","article-title":"Bimatoprost implant biodegradation in the phase 3, randomized, 20-month ARTEMIS studies","volume":"39","author":"Weinreb","year":"2023","journal-title":"J. Ocular Pharmacol. Ther."},{"key":"bfae49febib133","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.exer.2008.08.002","type":"journal-article","article-title":"The lens capsule","volume":"88","author":"Danysh","year":"2009","journal-title":"Exp. Eye Res."},{"key":"bfae49febib134","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/09205063.2020.1865691","type":"journal-article","article-title":"Antiproliferative drug-loaded multi-functionalized intraocular lens for reducing posterior capsular opacification","volume":"32","author":"Huang","year":"2021","journal-title":"J. Biomater. Sci., Polym. Ed."},{"key":"bfae49febib135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmbbm.2019.103600","type":"journal-article","article-title":"Biomechanical properties of the lens capsule: a review","volume":"103","author":"Avetisov","year":"2020","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"bfae49febib136","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1021\/acsbiomaterials.0c01705","type":"journal-article","article-title":"Drug-eluting hydrophilic coating modification of intraocular lens via facile dopamine self-polymerization for posterior capsular opacification prevention","volume":"7","author":"Liu","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"bfae49febib137","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.930540","type":"journal-article","article-title":"Rapid and economical drug-eluting IOL preparation via thermoresponsive agarose coating for effective posterior capsular opacification prevention","volume":"10","author":"Chen","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"bfae49febib138","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400481","type":"journal-article","article-title":"Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2","volume":"4","author":"Chew","year":"2025","journal-title":"NEJM Evidence"},{"key":"bfae49febib139","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1089\/jop.2023.0071","type":"journal-article","article-title":"Eyes on the prize: decoding the ophthalmic product regulations and intricacies of the US food and drug administration approval","volume":"39","author":"Hirani","year":"2023","journal-title":"J. Ocular Pharmacol. Ther."},{"key":"bfae49febib140","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1097\/IAE.0b013e318217373c","type":"journal-article","article-title":"Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans","volume":"31","author":"Meyer","year":"2011","journal-title":"Retina"},{"key":"bfae49febib141","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40123-022-00532-9","type":"journal-article","article-title":"Pharmacokinetics of the port delivery system with ranibizumab in the ladder phase 2 trial for neovascular age-related macular degeneration","volume":"11","author":"Wykoff","year":"2022","journal-title":"Ophthalmol. Ther."},{"key":"bfae49febib142","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaophthalmol.2025.0001","type":"journal-article","article-title":"Port delivery system with ranibizumab vs monitoring in nonproliferative diabetic retinopathy without macular edema: the Pavilion randomized clinical trial","volume":"143","author":"Pieramici","year":"2025","journal-title":"JAMA Ophthalmol."},{"key":"bfae49febib143","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","type":"journal-article","article-title":"Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the pagoda randomized clinical trial","volume":"143","author":"Khanani","year":"2025","journal-title":"JAMA Ophthalmol."},{"key":"bfae49febib144","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1167\/tvst.14.4.8","type":"journal-article","article-title":"Structural updates to the implant and refill needle of the port delivery platform","volume":"14","author":"Pieramici","year":"2025","journal-title":"Trans. Vis. Sci. Technol."},{"key":"bfae49febib145","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ajo.2024.11.009","type":"journal-article","article-title":"Refillable drug reservoirs for retinal vascular diseases","volume":"277","author":"Clark","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"bfae49febib146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.3.4.1","type":"journal-article","article-title":"One-year feasibility study of replenish micropump for intravitreal drug delivery: a pilot study","volume":"3","author":"Gutierrez-Hernandez","year":"2014","journal-title":"Trans. Vis. Sci. Technol."},{"key":"bfae49febib147","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/tvst.3.6.5","type":"journal-article","article-title":"Implantable micropump for drug delivery in patients with diabetic macular edema","volume":"3","author":"Humayun","year":"2014","journal-title":"Trans. Vis. Sci. Technol."},{"key":"bfae49febib148","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.oret.2024.08.005","type":"journal-article","article-title":"Endophthalmitis in eyes treated with the port delivery system with ranibizumab: summary of cases during clinical trial development","volume":"9","author":"Eichenbaum","year":"2025","journal-title":"Ophthalmol. Retina"},{"key":"bfae49febib149","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.oret.2022.05.011","type":"journal-article","article-title":"Management of key ocular adverse events in patients implanted with the port delivery system with ranibizumab","volume":"6","author":"Awh","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"bfae49febib150","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","type":"journal-article","article-title":"Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results","volume":"130","author":"Regillo","year":"2023","journal-title":"Ophthalmology"},{"key":"bfae49febib151","first-page":"p 93","type":"book","article-title":"Instrumentation and devices","author":"Chen","year":"2022"},{"key":"bfae49febib152","author":"Dhoot","year":"2025","type":"book"},{"key":"bfae49febib153","article-title":"How EyePoint Pharmaceuticals is developing sustained-release drug delivery for eye diseases","author":"Buntz","year":"2021","type":"web-resource"},{"key":"bfae49febib154","first-page":"28","type":"journal-article","article-title":"Optimal polymer attributes","volume":"20","author":"Blizzard","year":"2023","journal-title":"Retin Physician"},{"key":"bfae49febib155","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/archopht.1994.01090240037023","type":"journal-article","article-title":"Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial","volume":"112","author":"Martin","year":"1994","journal-title":"Arch. Ophthalmol."},{"key":"bfae49febib156","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1056\/NEJM199707103370203","type":"journal-article","article-title":"Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant","volume":"337","author":"G.I.S. Group","year":"1997","journal-title":"New Engl. J. Med."},{"key":"bfae49febib157","first-page":"131","type":"book","article-title":"Biomaterials for intraocular sustained drug delivery","author":"Yasukawa","year":"2016"},{"key":"bfae49febib158","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/archopht.1992.01080140044023","type":"journal-article","article-title":"Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device","volume":"110","author":"Sanborn","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"bfae49febib159","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archopht.1992.01080140111037","type":"journal-article","article-title":"Intravitreal sustained-release ganciclovir","volume":"110","author":"Smith","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"bfae49febib160","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2020.04.001","type":"journal-article","article-title":"Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results","volume":"127","author":"Jaffe","year":"2020","journal-title":"Ophthalmology"},{"key":"bfae49febib161","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","type":"journal-article","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four\u2013week results of a multicenter randomized clinical study","volume":"113","author":"Fluocinolone Acetonide Uveitis Study Group","year":"2006","journal-title":"Ophthalmology"},{"key":"bfae49febib162","article-title":"An update on local steroids for uveitis","author":"Arepalli","year":"2025","type":"web-resource"},{"key":"bfae49febib163","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","type":"journal-article","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"bfae49febib164","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00417-020-04614-x","type":"journal-article","article-title":"Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant","volume":"258","author":"Cai","year":"2020","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"bfae49febib165","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","type":"journal-article","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"bfae49febib166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122625","type":"journal-article","article-title":"Reverse engineering the Ozurdex dexamethasone intravitreal implant","volume":"634","author":"Costello","year":"2023","journal-title":"Int. J. Pharm."},{"key":"bfae49febib167","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejpb.2023.04.003","type":"journal-article","article-title":"Drug release mechanisms of high-drug-load, melt-extruded dexamethasone intravitreal implants","volume":"187","author":"Costello","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"bfae49febib168","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/780634","type":"journal-article","article-title":"Drug delivery implants in the treatment of vitreous inflammation","volume":"2013","author":"Wang","year":"2013","journal-title":"Mediators Inflamm."},{"key":"bfae49febib169","first-page":"66","type":"book","article-title":"Development of combination product drug delivery systems","author":"Stevenson","year":"2015"},{"key":"bfae49febib170","first-page":"3087","type":"conference-proceedings","article-title":"Mathematical modeling of triamcinolone acetonide drug release from the i-vation\u2122 intravitreal implant (a controlled release platform)","author":"Barnett","year":"2009"},{"key":"bfae49febib171","first-page":"4332","type":"journal-article","article-title":"I-VationTM TA: 24-month clinical results of the phase I safety and preliminary efficacy study","volume":"50","author":"Dugel","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib172","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","type":"journal-article","article-title":"Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection","volume":"110","author":"Kwak","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"bfae49febib173","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","type":"journal-article","article-title":"Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations","volume":"35","author":"Yang","year":"2015","journal-title":"Retina"},{"key":"bfae49febib174","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2147\/DDDT.S403259","type":"journal-article","article-title":"Intravitreal fluocinolone acetonide implant (ILUVIEN\u00ae) for the treatment of retinal conditions. a review of clinical studies","volume":"17","author":"Mushtaq","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"bfae49febib175","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100298","type":"journal-article","article-title":"Phase I NT-501 ciliary neurotrophic factor implant trial for primary open-angle glaucoma: safety, neuroprotection, and neuroenhancement","volume":"3","author":"Goldberg","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"bfae49febib176","first-page":"3680","type":"journal-article","article-title":"Continuous intraocular drug delivery lasting over a decade: ciliary neurotrophic factor (CNTF) secreted from Neurotech\u2019s NT-501 implanted in subjects with retinal degenerative disorders","volume":"64","author":"Kauper","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib177","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1073\/pnas.1018987108","type":"journal-article","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc. Natl Acad. Sci."},{"key":"bfae49febib178","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","type":"journal-article","article-title":"Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa","volume":"156","author":"Ciliary Neurotrophic Factor Retinitis Pigmentosa Study Groups","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"bfae49febib179","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2016.07.013","type":"journal-article","article-title":"Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants","volume":"170","author":"Birch","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"bfae49febib180","first-page":"2277","type":"journal-article","article-title":"Interim results of a dose escalation study of NT-503 encapsulated cell therapy for the treatment of choroidal neovascularization in AMD","volume":"56","author":"Loewenstein","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib181","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4103\/1673-5374.205093","type":"journal-article","article-title":"Delivery of therapeutics to posterior eye segment: cell-encapsulating systems","volume":"12","author":"Wong","year":"2017","journal-title":"Neural Regener. Res."},{"key":"bfae49febib182","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.oret.2023.03.001","type":"journal-article","article-title":"Randomized phase IIb study of brimonidine drug delivery system generation 2 for geographic atrophy in age-related macular degeneration","volume":"7","author":"Freeman","year":"2023","journal-title":"Ophthalmol. Retina"},{"key":"bfae49febib183","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/IAE.0000000000002789","type":"journal-article","article-title":"Phase 2 study of the safety and efficacy of brimonidine drug delivery system (Brimo DDS) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration","volume":"41","author":"Brimo DDS Gen 1 Study Group","year":"2021","journal-title":"Retina"},{"key":"bfae49febib184","first-page":"1938","type":"journal-article","article-title":"Design and function of EYP-1901, a sustained-release platform for retinal\/choroidal diseases: pan\u2013vascular endothelial growth factor receptor inhibitor vorolanib in a bioerodible intravitreal insert","volume":"65","author":"Kuppermann","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib185","first-page":"692","type":"journal-article","article-title":"LUGANO and LUCIA trial design: pivotal phase 3 studies of EYP-1901 vs aflibercept in wet age-related macular degeneration","volume":"66","author":"Patel","year":"2025","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib186","first-page":"4762","type":"journal-article","article-title":"PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy: 12-month results","volume":"66","author":"Almeida","year":"2025","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib187","first-page":"1984","type":"journal-article","article-title":"Pharmacokinetics of a 6 month sustained hydrogel delivery system for tyrosine kinase inhibitors in Dutch belted rabbits","volume":"58","author":"Jarrett","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib188","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/gels10030158","type":"journal-article","article-title":"Hydrogel-based therapy for age-related macular degeneration: current innovations, impediments, and future perspectives","volume":"10","author":"Zhang","year":"2024","journal-title":"Gels"},{"key":"bfae49febib189","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/IIO.0000000000000551","type":"journal-article","article-title":"Tyrosine kinase inhibitors: the next chapter in reducing treatment burden for exudative retinal diseases?","volume":"65","author":"Ravichandran","year":"2025","journal-title":"Int. Ophthalmol. Clin."},{"key":"bfae49febib190","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/17425247.2025.2516668","type":"journal-article","article-title":"Tyrosine kinase inhibitors and their promising role in treating diabetic retinopathy and other retinal vascular diseases: overview of their routes of administration, pharmacokinetics, formulations, and drug delivery applications","volume":"22","author":"Kadavil","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"bfae49febib191","doi-asserted-by":"publisher","first-page":"eaai8030","DOI":"10.1126\/scitranslmed.aai8030","type":"journal-article","article-title":"Tyrosine kinase blocking collagen IV\u2013derived peptide suppresses ocular neovascularization and vascular leakage","volume":"9","author":"Lima e Silva","year":"2017","journal-title":"Sci. Trans. Med."},{"key":"bfae49febib192","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122043","type":"journal-article","article-title":"A collagen IV\u2013derived peptide disrupts \u03b15\u03b21 integrin and potentiates Ang2\/Tie2 signaling","volume":"4","author":"Mirando","year":"2019","journal-title":"JCI Insight"},{"key":"bfae49febib193","article-title":"The role of angiopoietins in neovascular diabetes-related retinal diseases","author":"Jim\u00e9nez","year":"2022","type":"other"},{"key":"bfae49febib194","first-page":"63","type":"book","article-title":"Agents targeting angiopoietin\/tie pathway in diabetic macular edema","author":"Yip","year":"2023"},{"key":"bfae49febib195","first-page":"3304","type":"journal-article","article-title":"AXT107 an inhibitor of neovascularization, vascular leakage, and inflammation, is well-tolerated and could potentially be dosed once a year to treat retinal vascular diseases","volume":"62","author":"Pandey","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib196","first-page":"1705","author":"Ciulla","year":"2024","type":"report"},{"key":"bfae49febib197","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ophtha.2017.12.029","type":"journal-article","article-title":"Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, phase III trial","volume":"125","author":"Donnenfeld","year":"2018","journal-title":"Ophthalmology"},{"key":"bfae49febib198","first-page":"1825","type":"journal-article","article-title":"Results of a phase 3, randomized, double-masked, vehicle controlled study (phase 3c) evaluating the safety and efficacy of DEXTENZATM (dexamethasone insert) 0.4 mg for the treatment of ocular inflammation and pain after cataract surgery","volume":"58","author":"Talamo","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib199","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.2147\/OPTH.S476419","type":"journal-article","article-title":"Multicenter phase 3 clinical trial evaluating intracanalicular dexamethasone insert for the treatment of allergic conjunctivitis","volume":"18","author":"Kenyon","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"bfae49febib200","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/j.jcrs.0000000000000414","type":"journal-article","article-title":"Safety and efficacy of nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery","volume":"47","author":"Donnenfeld","year":"2021","journal-title":"J. Cataract Refract. Surg."},{"key":"bfae49febib201","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/j.jcrs.0000000000000514","type":"journal-article","article-title":"Comment on: safety and efficacy of a nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery","volume":"47","author":"Grzybowski","year":"2021","journal-title":"J. Cataract Refract. Surg."},{"key":"bfae49febib202","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ophtha.2019.11.005","type":"journal-article","article-title":"Prescribing patterns and costs associated with postoperative eye drop use in Medicare beneficiaries undergoing cataract surgery","volume":"127","author":"Zafar","year":"2020","journal-title":"Ophthalmology"},{"key":"bfae49febib203","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/IIO.0000000000000560","type":"journal-article","article-title":"Dropless cataract surgery: a review of the literature","volume":"65","author":"Rao","year":"2025","journal-title":"Int. Ophthalmol. Clin."},{"key":"bfae49febib204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2021.10.006","type":"journal-article","article-title":"Cataract in the adult eye preferred practice pattern\u00ae","volume":"129","author":"Miller","year":"2022","journal-title":"Ophthalmology"},{"key":"bfae49febib205","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.ophtha.2016.04.026","type":"journal-article","article-title":"Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study","volume":"123","author":"Brandt","year":"2016","journal-title":"Ophthalmology"},{"key":"bfae49febib206","first-page":"5073","type":"journal-article","article-title":"Sustained delivery of prostaglandin from drug-containing depots using ocular rings in beagles","volume":"54","author":"Crawford","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib207","first-page":"481","type":"journal-article","article-title":"Continuous wear non-invasive device for sustained ocular drug delivery","volume":"55","author":"Leahy","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib208","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ijbiomac.2018.01.029","type":"journal-article","article-title":"Sustained release timolol maleate loaded ocusert based on biopolymer composite","volume":"110","author":"Nair","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"bfae49febib209","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18240\/ijo.2021.01.21","type":"journal-article","article-title":"Sustained-release drug delivery systems for the treatment of glaucoma","volume":"14","author":"Kesav","year":"2021","journal-title":"Int. J. Ophthalmol."},{"key":"bfae49febib210","article-title":"Mati therapeutics announces completion of manufacturing facility dedicated to global production of all punctal plug delivery system (PPDS) products 2023","author":"Therapeutics","type":"web-resource"},{"key":"bfae49febib211","first-page":"2765","type":"journal-article","article-title":"Phase 1 study of an intracameral travoprost hydrogel-based implant for the treatment of POAG and ocular hypertension","volume":"62","author":"Goldberg","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib212","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.2147\/OPTH.S427976","type":"journal-article","article-title":"Phase 3, randomized study comparing intracameral bimatoprost implant 15 \u03bcg and selective laser trabeculectomy in patients with open-angle glaucoma or ocular hypertension","volume":"17","author":"Christie","year":"2023","journal-title":"Clin. Ophthalmol."},{"key":"bfae49febib213","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40123-024-00898-y","type":"journal-article","article-title":"Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial","volume":"13","author":"Sarkisian","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"bfae49febib214","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2025.100163","type":"journal-article","article-title":"Drug delivery systems in glaucoma\u2013current innovations and future perspectives","volume":"14","author":"Tan","year":"2025","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"bfae49febib215","article-title":"PER-001, an endothelin antagonist, increased optic nerve head blood flow with structural and functional improvements in patients with glaucoma","author":"Mansberger","year":"2025","type":"book"},{"key":"bfae49febib216","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.maturitas.2022.05.002","type":"journal-article","article-title":"Glaucoma\u2013risk factors and current challenges in the diagnosis of a leading cause of visual impairment","volume":"163","author":"Lee","year":"2022","journal-title":"Maturitas"},{"key":"bfae49febib217","first-page":"158","type":"book","article-title":"Ocular surface disease and anti-glaucoma medications: various features, diagnosis, and management guidelines","author":"Andole","year":"2023"},{"key":"bfae49febib218","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/JAPAJ.JAPAJ_49_25","type":"journal-article","article-title":"Revolutionizing glaucoma treatment: the FDA-approved iDose\u2122 Travoprost Intracameral Implant","volume":"3","author":"Dalabeh","year":"2025","journal-title":"JAPA Acad. J."},{"key":"bfae49febib219","doi-asserted-by":"publisher","DOI":"10.1016\/j.porgcoat.2024.108578","type":"journal-article","article-title":"Preparation of tannic acid based zwitterionic polymer functionalized coating on glass surface for antibacterial and antifouling applications","volume":"194","author":"Wu","year":"2024","journal-title":"Prog. Org. Coat."},{"key":"bfae49febib220","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1039\/D0BM00155D","type":"journal-article","article-title":"Antibiofilm coatings based on protein-engineered polymers and antimicrobial peptides for preventing implant-associated infections","volume":"8","author":"Acosta","year":"2020","journal-title":"Biomater. Sci."},{"key":"bfae49febib221","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jconrel.2023.08.047","type":"journal-article","article-title":"Intravitreal implants manufactured by supercritical foaming for treating retinal diseases","volume":"362","author":"Bendicho-Lavilla","year":"2023","journal-title":"J. Control. Release"},{"key":"bfae49febib222","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1208\/s12248-009-9143-y","type":"journal-article","article-title":"Nonviral gene delivery: principle, limitations, and recent progress","volume":"11","author":"Al-Dosari","year":"2009","journal-title":"AAPS J."},{"key":"bfae49febib223","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/pharmaceutics15010025","type":"journal-article","article-title":"Optimization of an injectable hydrogel depot system for the controlled release of retinal-targeted hybrid nanoparticles","volume":"15","author":"Ottonelli","year":"2022","journal-title":"Pharmaceutics"},{"key":"bfae49febib224","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3390\/pharmaceutics15020611","type":"journal-article","article-title":"A multifunctional hybrid nanocarrier for non-invasive siRNA delivery to the retina","volume":"15","author":"Nishida","year":"2023","journal-title":"Pharmaceutics"},{"key":"bfae49febib225","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/tvst.9.13.21","type":"journal-article","article-title":"Suprachoroidally delivered DNA nanoparticles transfect retina and retinal pigment epithelium\/choroid in rabbits","volume":"9","author":"Kansara","year":"2020","journal-title":"Trans. Vis. Sci. Technol."},{"key":"bfae49febib226","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2460671","type":"journal-article","article-title":"Safety and biocompatibility of a novel biodegradable aflibercept-drug delivery system in rhesus macaques","volume":"32","author":"Story","year":"2025","journal-title":"Drug Deliv."},{"key":"bfae49febib227","first-page":"4459","type":"journal-article","article-title":"Alkaline hydrolysis of poly (ethylene terepthalate) yarn for improving cell attachment and long-term viability in the NT-501 intraocular device","volume":"44","author":"Thanos","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib228","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000336045","type":"journal-article","article-title":"Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results","volume":"227","author":"Tetz","year":"2012","journal-title":"Ophthalmologica"},{"key":"bfae49febib229","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/adhm.201300696","type":"journal-article","article-title":"Particle\u2010stabilized emulsion droplets for gravity\u2010mediated targeting in the posterior segment of the eye","volume":"3","author":"Kim","year":"2014","journal-title":"Adv. Healthcare Mater."},{"key":"bfae49febib230","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","type":"journal-article","article-title":"Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly (lactic acid) microspheres for the treatment of glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J. Control. Release"},{"key":"bfae49febib231","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1167\/iovs.17-23758","type":"journal-article","article-title":"Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing","volume":"59","author":"Jung","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib232","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jconrel.2022.10.036","type":"journal-article","article-title":"Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space","volume":"352","author":"Jung","year":"2022","journal-title":"J. Control. Release"},{"key":"bfae49febib233","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1021\/mp300716t","type":"journal-article","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"bfae49febib234","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jconrel.2018.05.030","type":"journal-article","article-title":"Intravitreal implantable magnetic micropump for on-demand VEGFR-targeted drug delivery","volume":"283","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"key":"bfae49febib235","doi-asserted-by":"publisher","first-page":"eaat4388","DOI":"10.1126\/sciadv.aat4388","type":"journal-article","article-title":"A swarm of slippery micropropellers penetrates the vitreous body of the eye","volume":"4","author":"Wu","year":"2018","journal-title":"Sci. Adv."},{"key":"bfae49febib236","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1664968","type":"journal-article","article-title":"Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies","volume":"16","author":"Ma","year":"2025","journal-title":"Front. Immunol."},{"key":"bfae49febib237","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3390\/pharmaceutics17111405","type":"journal-article","article-title":"Base and prime editing for inherited retinal diseases: delivery platforms, safety, efficacy, and translational perspectives","volume":"17","author":"Zhang","year":"2025","journal-title":"Pharmaceutics"},{"key":"bfae49febib238","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s40265-025-02237-2","type":"journal-article","article-title":"Can gene therapy transform the treatment landscape of posterior segment eye diseases? A comprehensive review of recent advancements","volume":"85","author":"Chen","year":"2025","journal-title":"Drugs"},{"key":"bfae49febib239","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40942-021-00325-5","type":"journal-article","article-title":"Pipeline therapies for neovascular age related macular degeneration","volume":"7","author":"Arepalli","year":"2021","journal-title":"Int. J. Retina Vitreous"},{"key":"bfae49febib240","first-page":"5307","type":"journal-article","article-title":"Determining the function of NT-501 produced CNTF at physiological levels in human retinas","volume":"66","author":"Laughlin","year":"2025","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib241","first-page":"628","type":"journal-article","article-title":"Effect of membrane porosity on CNTF delivery using the NT-501 micronized device","volume":"48","author":"McGovern","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"bfae49febib242","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jamaophthalmol.2024.1119","type":"journal-article","article-title":"UV light is not a toy\u2014recreational use and eye harm","volume":"142","author":"Woodward","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"bfae49febib243","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.xphs.2020.09.043","type":"journal-article","article-title":"Long-term stability of anti-vascular endothelial growth factor (a-VEGF) biologics under physiologically relevant conditions and its impact on the development of long-acting delivery systems","volume":"110","author":"Chang","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"bfae49febib244","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev-bioeng-110122-121128","type":"journal-article","article-title":"Lessons learned and challenges ahead in the translation of implantable microscale sensors and actuators","volume":"27","author":"Park","year":"2025","journal-title":"Ann. Rev. Biomed. Eng."},{"key":"bfae49febib245","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40942-023-00446-z","type":"journal-article","article-title":"Port delivery system with ranibizumab (Susvimo) recall-what does it mean to the retina specialists","volume":"9","author":"Sharma","year":"2023","journal-title":"Int. J. Retina Vitreous"},{"key":"bfae49febib246","doi-asserted-by":"publisher","first-page":"8411","DOI":"10.1021\/acsnano.4c12726","type":"journal-article","article-title":"Micro-and nanomotors: engineered tools for targeted and efficient biomedicine","volume":"19","author":"Ruiz-Gonzalez","year":"2025","journal-title":"ACS Nano"},{"key":"bfae49febib247","doi-asserted-by":"publisher","first-page":"27888","DOI":"10.1021\/acsomega.3c07033","type":"journal-article","article-title":"Magnetically controlled intraocular delivery of dexamethasone using silica-coated magnetic nanoparticles","volume":"9","author":"Noh","year":"2024","journal-title":"ACS Omega"},{"key":"bfae49febib248","first-page":"1","type":"book","article-title":"Introduction of 3D printing and different bioprinting methods","author":"Biswas","year":"2024"},{"key":"bfae49febib249","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41587-023-01774-z","type":"journal-article","article-title":"A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines","volume":"42","author":"Vander Straeten","year":"2024","journal-title":"Nat. Biotechnol."}],"container-title":["Biofabrication"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:32:12Z","timestamp":1773653532000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1758-5090\/ae49fe"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":249,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1088\/1758-5090\/ae49fe","relation":{},"ISSN":["1758-5082","1758-5090"],"issn-type":[{"value":"1758-5082","type":"print"},{"value":"1758-5090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"Implantable ocular therapeutic systems: an insight into their clinical potential in the long-term treatment of ocular diseases","name":"article_title","label":"Article Title"},{"value":"Biofabrication","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2026 The Author(s). Published by IOP Publishing Ltd","name":"copyright_information","label":"Copyright Information"},{"value":"2025-11-05","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-02-24","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-03-16","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}